Christos Petridis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Christos Petridis has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Douglas F. Easton
Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge , Cambridge CB1 8RN
17 shared publications - Elinor J. Sawyer
School of Cancer & Pharmaceutical Sciences, Comprehensive Cancer Centre, Guy’s Campus, King’s College London, London, UK
17 shared publications - Jasmine Timbres
Breast Cancer Genetics, King’s College London, London, United Kingdom
17 shared publications - Kelly Kohut
Department of Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter, UK
17 shared publications - Marjanka K. Schmidt
Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, 1066 CX, The Netherlands.
17 shared publications - Nasim Mavaddat
Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK
17 shared publications
Latest Publications
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 4 from Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease
Table S4. Univariate and multivariate Cox regression models for recurrence-free survival (RFS) and disease-free survival (DFS) after DCIS and continuous ER-positive PRS.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 4 from Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease
Table S4. Univariate and multivariate Cox regression models for recurrence-free survival (RFS) and disease-free survival (DFS) after DCIS and continuous ER-positive PRS.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease
Table S1. Genotyped and imputed (not genotyped) SNPs
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease
Table S1. Genotyped and imputed (not genotyped) SNPs
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table 3 from Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease
Univariate and multivariate Cox regression including continuous overall PRS in DCIS and LCIS.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 3 from Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease
Univariate and multivariate Cox regression including continuous overall PRS in DCIS and LCIS.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 11 from Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease
Table S11. Univariate and multivariate Cox regression models comparing risk of developing invasive ipsilateral recurrence after DCIS or LCIS.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 11 from Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease
Table S11. Univariate and multivariate Cox regression models comparing risk of developing invasive ipsilateral recurrence after DCIS or LCIS.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 6 from Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease
Table S6. Univariate Cox regression models for PRS and outcomes after DCIS, stratified by family history of breast cancer.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 6 from Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease
Table S6. Univariate Cox regression models for PRS and outcomes after DCIS, stratified by family history of breast cancer.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table 2 from Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease
Follow-up data and cumulative incidence of events over the follow-up period.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease
Follow-up data and cumulative incidence of events over the follow-up period.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 3 from Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease
Table S3. Univariate and multivariate Cox regression models for overall PRS quartiles and recurrence-free survival (RFS), disease-free survival (DFS), and contralateral disease-free survival (CDFS) after DCIS.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 3 from Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease
Table S3. Univariate and multivariate Cox regression models for overall PRS quartiles and recurrence-free survival (RFS), disease-free survival (DFS), and contralateral disease-free survival (CDFS) after DCIS.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 10 from Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease
Table S10. Univariate and multivariate Cox regression models for overall PRS and outcomes after LCIS, in those with a positive family history of breast cancer, and excluding those treated with radiotherapy or mastectomy (N=64).
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 10 from Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease
Table S10. Univariate and multivariate Cox regression models for overall PRS and outcomes after LCIS, in those with a positive family history of breast cancer, and excluding those treated with radiotherapy or mastectomy (N=64).
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 7 from Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease
Table S7. Univariate and multivariate Cox regression models for overall PRS and outcomes after DCIS, in those with no family history of breast cancer, and excluding those treated with radiotherapy or mastectomy (N=520).
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 7 from Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease
Table S7. Univariate and multivariate Cox regression models for overall PRS and outcomes after DCIS, in those with no family history of breast cancer, and excluding those treated with radiotherapy or mastectomy (N=520).
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease
Table S2. Univariate and multivariate Cox regression models for recurrence-free survival (RFS) and disease-free survival (DFS) after DCIS and continuous overall PRS.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease
Table S2. Univariate and multivariate Cox regression models for recurrence-free survival (RFS) and disease-free survival (DFS) after DCIS and continuous overall PRS.